Skip to main content
OpenTrials
Completed

NCT Number: NCT02246725

Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.

In this trial, patients with cancer in the upper gastrointestinal canal who are going to receive first line palliative chemotherapy and patients with colorectal cancer who are going to receive second line palliative chemotherapy will be included. Participating patients will be randomized between early contact with a palliative care unit, or contact with a palliative care unit when needed. The objectives with the trial is to investigate if an early establishment with a palliative care unit will have a positive impact on the patients quality of life, this also applies for the nearest relative, survival, and if a difference in numbers of chemotherapy cycles can be detected.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer Behavior Behavioral Symptoms Colonic Diseases Colorectal Neoplasms Depression Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Lund University Hospital

Lund, 221 85, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with tumor in upper gastrointestinal canal, who is going to start treatment with first line palliative chemotherapy
  • Patients with colorectal cancer, who is going to start treatment with second line palliative chemotherapy
  • Signed written informed concent

Exclusion criteria

  • Patients with neuroendocrine tumor
  • Patients with already ongoing chemotherapy
  • Patients with already established contact with palliative care unit

Treatment and study plan

Contact with palliative care unit.

Other

Primary outcomes

  1. Quality of Life, such as pain, anxiety.

    Time frame: At baseline, every 6th week until death (approximately 1 year). The patients relative will be followed similarly until patients death and then every 12th week for 1 year.

    Evaluation will be performed by different quality of life forms sent to the patient every 6th week, and by telephone contact with a study nurse every 6th week until patients death. The same also applies for the patients nearest relative; quality of life forms will be sent every 12th week for additional 1 year.

Secondary outcomes

  1. Survival

    Time frame: Approximately 12 months.

Other outcomes

  1. Numbers of chemotherapy cycles

    Time frame: Approximately 12 months.

Sponsors and collaborators

Lead sponsor

Lund University Hospital

Other

Registry information

Acronym: ALLAN

Important dates

Study start
2014
Primary completion
2025
Study completion
2025
First posted
Sep 23, 2014
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.